CERo Therapeutics received FDA clearance for a second IND application to begin Phase 1 trials of CER-1236 in non-small cell lung cancer and ovarian cancer patients.
CERo Therapeutics has strengthened its financial position with a $5 million financing round, bringing total cash reserves to $8 million for advancing its innovative immunotherapy pipeline.
CERO Therapeutics received FDA clearance for its IND application for CER-1236, a genetically engineered human immune cell therapy, on November 15, 2024.
CERo Therapeutics has received FDA clearance for its Investigational New Drug Application for CER-1236, a novel treatment for acute myelogenous leukemia (AML).
CERo Therapeutics received FDA clearance for its Investigational New Drug application to begin Phase 1 clinical trials of CER-1236 in acute myelogenous leukemia (AML).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.